ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. Yet company CEO Hervé Hoppenot views the antibody molecule not necessarily as a major revenue driver but as an aide to the company’s oncology pipeline.